LGALS3 and hydrops fetalis: Furthermore, both galectin-3 and sST2 were recommended for risk stratification in the 2013 ACCF/AHA guidelines on HF (38) and its updates in 2017 (39), but they remain without evidence of an incremental management benefit (40).